Tabla 1 )
At the primary level, host-related factors, including baseline metabolic status, insulin resistance, -cell function, inflammatory burden, and genetic background, represent the dominant drivers of therapeutic response
Its backed by years of research, and more importantly, by the people who are living it day by day
While dual receptor co-agonism offers enhanced weight loss and metabolic benefits, it also appears to offer upside in mitigating GI AEs
Tirzepatide has already been approved by the FDA for the management of chronic weight in adults who are either obese or overweight and have at least one condition related to weight
Use a sharps container: Always put used pens and needles in an FDA-approved sharps container